October 1, 2018

BlinkBio, Inc.

Developer of a drug conjugate therapies designed to improve on the safety and efficacy of contemporary antibody drug conjugates (ADCs). The company is assembling a proprietary suite of assets that will develop tunable drug conjugates in order to achieve an optimal Therapeutic Index (TI), delivering anti-cancer medicines inside the tumor cell and within the tumor microenvironment while minimizing toxicities to the patient and directly targeting the delivery of toxins to tumors.